IL42317A - Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazine - Google Patents
Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazineInfo
- Publication number
- IL42317A IL42317A IL42317A IL4231773A IL42317A IL 42317 A IL42317 A IL 42317A IL 42317 A IL42317 A IL 42317A IL 4231773 A IL4231773 A IL 4231773A IL 42317 A IL42317 A IL 42317A
- Authority
- IL
- Israel
- Prior art keywords
- seryl
- hydrazine
- trihydroxybenzyl
- hydroxytryptophan
- pharmaceutically acceptable
- Prior art date
Links
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 title claims 6
- 229960002888 oxitriptan Drugs 0.000 title claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 title claims 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 title claims 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims 3
- 206010022437 insomnia Diseases 0.000 title claims 3
- 150000003839 salts Chemical class 0.000 claims 8
- 238000000034 method Methods 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 3
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH984672 | 1972-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL42317A0 IL42317A0 (en) | 1973-07-30 |
| IL42317A true IL42317A (en) | 1976-04-30 |
Family
ID=4356299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL42317A IL42317A (en) | 1972-06-30 | 1973-05-21 | Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazine |
Country Status (18)
| Country | Link |
|---|---|
| AT (1) | AT338412B (en:Method) |
| AU (1) | AU476456B2 (en:Method) |
| BE (1) | BE801645A (en:Method) |
| CA (1) | CA1015272A (en:Method) |
| DD (1) | DD107592A5 (en:Method) |
| DE (1) | DE2327636A1 (en:Method) |
| ES (1) | ES416383A1 (en:Method) |
| FR (1) | FR2190453B1 (en:Method) |
| GB (1) | GB1369189A (en:Method) |
| HU (1) | HU167292B (en:Method) |
| IE (1) | IE37833B1 (en:Method) |
| IL (1) | IL42317A (en:Method) |
| LU (1) | LU67898A1 (en:Method) |
| NL (1) | NL7308435A (en:Method) |
| PH (1) | PH9584A (en:Method) |
| SE (1) | SE407744B (en:Method) |
| SU (1) | SU533323A3 (en:Method) |
| ZA (1) | ZA733284B (en:Method) |
-
1973
- 1973-05-15 ZA ZA733284A patent/ZA733284B/xx unknown
- 1973-05-18 AU AU55897/73A patent/AU476456B2/en not_active Expired
- 1973-05-21 IL IL42317A patent/IL42317A/en unknown
- 1973-05-30 DE DE19732327636 patent/DE2327636A1/de active Pending
- 1973-06-18 NL NL7308435A patent/NL7308435A/xx not_active Application Discontinuation
- 1973-06-22 IE IE1034/72A patent/IE37833B1/xx unknown
- 1973-06-27 FR FR7323456A patent/FR2190453B1/fr not_active Expired
- 1973-06-28 LU LU67898A patent/LU67898A1/xx unknown
- 1973-06-28 CA CA175,140A patent/CA1015272A/en not_active Expired
- 1973-06-28 PH PH14782*UA patent/PH9584A/en unknown
- 1973-06-28 SU SU1940152A patent/SU533323A3/ru active
- 1973-06-28 ES ES416383A patent/ES416383A1/es not_active Expired
- 1973-06-29 AT AT574273A patent/AT338412B/de not_active IP Right Cessation
- 1973-06-29 HU HUHO1588A patent/HU167292B/hu unknown
- 1973-06-29 GB GB3107173A patent/GB1369189A/en not_active Expired
- 1973-06-29 SE SE7309254A patent/SE407744B/xx unknown
- 1973-06-29 DD DD171943A patent/DD107592A5/xx unknown
- 1973-06-29 BE BE132885A patent/BE801645A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE407744B (sv) | 1979-04-23 |
| FR2190453A1 (en:Method) | 1974-02-01 |
| ZA733284B (en) | 1974-03-27 |
| ES416383A1 (es) | 1976-02-16 |
| GB1369189A (en) | 1974-10-02 |
| AU476456B2 (en) | 1976-09-23 |
| NL7308435A (en:Method) | 1974-01-02 |
| AT338412B (de) | 1977-08-25 |
| SU533323A3 (ru) | 1976-10-25 |
| CA1015272A (en) | 1977-08-09 |
| LU67898A1 (en:Method) | 1975-04-11 |
| ATA574273A (de) | 1976-12-15 |
| IE37833B1 (en) | 1977-10-26 |
| IE37833L (en) | 1973-12-30 |
| FR2190453B1 (en:Method) | 1976-04-09 |
| DE2327636A1 (de) | 1974-01-17 |
| BE801645A (fr) | 1974-01-02 |
| DD107592A5 (en:Method) | 1974-08-12 |
| PH9584A (en) | 1976-01-19 |
| HU167292B (en:Method) | 1975-09-27 |
| AU5589773A (en) | 1974-11-21 |
| IL42317A0 (en) | 1973-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1274402B1 (en) | Pharmaceutical composition for the controlled release of paracetamol | |
| US5859060A (en) | Timed release tablet comprising naproxen and pseudoepherine | |
| ES2240033T5 (es) | Comprimido matricial de liberación prolongada de trimetazidina tras su administración por vía oral | |
| HU892559D0 (en) | Process for the preparation of transdermal pharmaceutical composition suitable for systemic administration, containing deprenyl as active ingredient | |
| JPH02270820A (ja) | 徐放性エトドラク | |
| AU2001260212A1 (en) | Composition | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| CN105687177A (zh) | N-乙酰半胱氨酸组合物以及改善对乙酰氨基酚的治疗效能的方法 | |
| JPS6357405B2 (en:Method) | ||
| CA1182049A (en) | Apap antacid composition | |
| IL43820A (en) | Pharmacological preparations for the treatment of deformed disabled, containing symptomatic aminophytic bronchodilators | |
| IL42317A (en) | Pharmaceutical preparations active against depression and insomnia,containing l-5-hydroxytryptophan together with n1-(d,l-seryl)-n2-(2,3,4,-trihydroxybenzyl)-hydrazine | |
| PT891186E (pt) | Administração nasal de agentes para o tratamento de emese tardia | |
| US2427887A (en) | Analgesic composition | |
| US5292497A (en) | Method of reducing chemotherapy toxicity using (methylaminopropylamino)propyl dihydrogen phosphorothioate | |
| US2906665A (en) | L-amphetamine alginate | |
| GB2061111A (en) | Long acting pharmaceutical composition | |
| GB1464467A (en) | Pharmaceutical composition for the treatment of coronary | |
| JP2005502690A5 (en:Method) | ||
| RU2150273C1 (ru) | Антигипоксическое и актопротекторное средство | |
| IE37288B1 (en) | Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children | |
| IL29570A (en) | Preparations for the treatment of leukoma containing a history of 5, 01 - Epoxy - H5 - Dibenzo] a, d [Cyclohapthen | |
| JPH0113449B2 (en:Method) | ||
| GB1375806A (en:Method) | ||
| SU1165234A3 (ru) | Способ получени @ -аллил-5-хлор- @ -(4,5-дигидро-1 @ -имидазол-2-ил)-2,1,3-бензотиадиазол-4-амина или его кислотно-аддитивных солей |